Moaddel, Ruin
Shardell, Michelle
Khadeer, Mohammed
Lovett, Jacqueline
Kadriu, Bashkim
Ravichandran, Sarangan
Morris, Patrick J.
Yuan, Peixiong
Thomas, Craig J.
Gould, Todd D.
Ferrucci, Luigi
Zarate, Carlos A.
Funding for this research was provided by:
National Institutes of Health
Article History
Received: 22 June 2018
Accepted: 30 July 2018
First Online: 16 August 2018
Compliance with ethical standards
: The study was approved by the Combined Neuroscience Institutional Review Board (IRB) at the National Institutes of Health (NIH). All subjects provided written informed consent before entry into the study. Informed consents and ongoing study participation for patients with MDD were monitored by the Human Subjects Protection Office at NIH (NCT00088699).
: C.A.Z. is listed as a co-inventor on a patent application for the use of ketamine in major depression. R.M. and C.A.Z. are listed as co-inventors on a patent for the use of (2R,6R)-hydroxynorketamine, (S)-dehydronorketamine, and other stereoisomeric dehydro- and hydroxylated metabolites of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain. R.M., P.M., C.J.T., T.D.G., and C.A.Z are listed as co-inventors on a patent application for the use of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. R.M., P.M., C.J.T., and C.A.Z have assigned their patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. T.D.G has assigned their patent rights to the University of Maryland Baltimore but will share a percentage of any royalties that may be received by the University of Maryland Baltimore.